Title: Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells.
Journal: The Journal of biological chemistry 20170825
Title: Insulin resistance induces posttranslational hepatic sortilin 1 degradation in mice.
Journal: The Journal of biological chemistry 20150501
Title: A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120801
Title: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Journal: Pigment cell & melanoma research 20120301
Title: Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.
Journal: International journal of cancer 20110215
Title: Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma.
Journal: Neuro-oncology 20100601
Title: Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
Journal: Molecular cancer therapeutics 20090101
Title: Synthesis and structure-activity relationships of ring-opened 17-hydroxywortmannins: potent phosphoinositide 3-kinase inhibitors with improved properties and anticancer efficacy.
Journal: Journal of medicinal chemistry 20080313
Title: Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer.
Journal: PloS one 20080101
Title: The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
Journal: Molecular cancer therapeutics 20070901
Title: The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signaling.
Journal: Cancer chemotherapy and pharmacology 20061001
Title: The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Journal: Molecular cancer therapeutics 20050901
Title: Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling.
Journal: Molecular cancer therapeutics 20040701
Title: Ihle NT, et al. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growthfactor receptor inhibitor ZD1839 in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther. 2005 Sep;4(9):1349-57.
Title: Bowles DW, et al. A Randomized, Phase II Trial of C225 With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clin Colorectal Cancer. 2016 Dec;15(4):337-344.e2.
Title: Sonolisib
